Loading
PDBj
メニューPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6IJS

Human PPARgamma ligand binding domain complexed with SB1494

6IJS の概要
エントリーDOI10.2210/pdb6ijs/pdb
分子名称Peroxisome proliferator-activated receptor gamma, 16-mer peptide from Nuclear receptor coactivator 1, N-{[3-({[(1R,2S)-2-{[(2E)-2-cyano-4,4-dimethylpent-2-enoyl]amino}cyclopentyl]oxy}methyl)phenyl]methyl}-4-[(4-methylpiperazin-1-yl)methyl]benzamide, ... (4 entities in total)
機能のキーワードtype 2 diabetes, nuclear receptor, inhibitor, ligand binding domain, transcription
由来する生物種Homo sapiens (Human)
詳細
タンパク質・核酸の鎖数2
化学式量合計33798.33
構造登録者
Jang, J.Y.,Han, B.W. (登録日: 2018-10-11, 公開日: 2019-10-16, 最終更新日: 2024-10-23)
主引用文献Jang, J.Y.,Kim, H.,Kim, H.J.,Suh, S.W.,Park, S.B.,Han, B.W.
Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPAR gamma phosphorylation.
Sci Rep, 9:11168-11168, 2019
Cited by
PubMed Abstract: Peroxisome proliferator-activated receptor γ (PPARγ) is a major therapeutic target for the treatment of type 2 diabetes. However, the use of PPARγ-targeted drugs, such as rosiglitazone and pioglitazone, is limited owing to serious side effects caused by classical agonism. Using a rational drug discovery approach, we recently developed SB1495, a novel reversible covalent inhibitor of the cyclin-dependent kinase 5 (Cdk5)-mediated phosphorylation of PPARγ at Ser245, a key factor in the insulin-sensitizing effect of PPARγ-targeted drugs. In this study, we report the crystal structures of PPARγ in complex with SB1495 and its enantiomeric analogue SB1494, which rarely exhibits inhibitory activity, to visualize the mechanistic basis for their distinct activities. SB1495 occupies the Arm3 region near the Ω loop of the PPARγ ligand-binding domain, whereas its enantiomeric analogue SB1494 binds to the Arm2 region. In addition, the piperazine moiety of SB1495 directly pushes the helix H2', resulting in the stabilization of the Ω loop just behind the helix H2'. Our results may contribute to the development of a new generation of antidiabetic drugs that selectively block PPARγ phosphorylation without classical agonism.
PubMed: 31371757
DOI: 10.1038/s41598-019-47672-w
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.15 Å)
構造検証レポート
Validation report summary of 6ijs
検証レポート(詳細版)ダウンロードをダウンロード

226707

件を2024-10-30に公開中

PDB statisticsPDBj update infoContact PDBjnumon